Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 6:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: scopolamine Clear all
Completed Phase 4 Interventional Results available

Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).

NCT00523991
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 80 Years
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
17
States / cities
Birmingham, Alabama • Jasper, Alabama • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 25, 2026, 6:28 PM EDT
Not listed Phase 1 Interventional

Effects of Anticholinergic or Long-Acting Beta 2 Agonist on FeNO and Pulmonary Function in SCI

NCT01355991
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Tiotropium, Salmeterol
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2015 · Synced Sep 25, 2026, 6:28 PM EDT
Completed No phase listed Observational Results available

A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)

NCT05169424
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Trelegy Ellipta, Stiolto Respimat, Tiotropium + Olodaterol (5/5 mcg), Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)
Device · Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
9,117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Sep 25, 2026, 6:28 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)

NCT00900731
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol, Placebo to tiotropium
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
1,598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Sep 25, 2026, 6:28 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion

NCT04947423
View directory record Official record
Conditions
Motion Sickness
Interventions
DPI-386 Nasal Gel, Placebo
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Sep 25, 2026, 6:28 PM EDT
Completed Phase 3 Interventional

A Multiple Dose Comparison of Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol.

NCT00274560
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Salmeterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
20
States / cities
Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Sep 25, 2026, 6:28 PM EDT
Completed Phase 4 Interventional Results available

Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection

NCT01483625
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
27
States / cities
Tucson, Arizona • Riverside, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Sep 25, 2026, 6:28 PM EDT
Completed Phase 2 Interventional Results available

Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT03118765
View directory record Official record
Conditions
Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
Interventions
GSP304 (tiotropium bromide) Inhalation Solution, GSP304 Placebo Inhalation Solution, Spiriva® Respimat® inhalation spray
Drug
Lead sponsor
Glenmark Specialty S.A.
Industry
Eligibility
40 Years to 85 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
25
States / cities
Andalusia, Alabama • Phoenix, Arizona • Tempe, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Sep 25, 2026, 6:28 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD

NCT00239447
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, HandiHaler, Respimat SMI
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
10
States / cities
Little Rock, Arkansas • San Diego, California • San Jose, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Sep 25, 2026, 6:28 PM EDT
Completed Phase 2 Interventional Results available

PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD

NCT01566773
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
PT001 MDI, Tiotropium Bromide, PT001 Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
10
States / cities
Fullerton, California • Clearwater, Florida • Panama City, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Sep 25, 2026, 6:28 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation

NCT00578968
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD
Interventions
Tiotropium, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Sep 25, 2026, 6:28 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray

NCT02155309
View directory record Official record
Conditions
Motion Sickness
Interventions
Scopolamine, Placebo
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Sep 25, 2026, 6:28 PM EDT
Completed Phase 3 Interventional Results available

24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease

NCT01316913
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GSK573719, tiotropium bromide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
872 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
20
States / cities
Jasper, Alabama • Mobile, Alabama • Huntington Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 25, 2026, 6:28 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy

NCT03435003
View directory record Official record
Conditions
Post-operative Nausea and Vomiting, Laparoscopic Sleeve Gastrectomy
Interventions
Aprepitant 80 mg Oral Capsule, scopolamine transdermal, Total intravenous anesthesia, Dexamethasone, Ondansetron, Reglan, Compazine, Sugammadex, Propofol, dexmedetomidine, Fentanyl, Sevoflurane, Desflurane
Drug · Procedure
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Sep 25, 2026, 6:28 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness

NCT04184115
View directory record Official record
Conditions
Motion Sickness
Interventions
DPI-386 Nasal Gel, Placebos
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Sep 25, 2026, 6:28 PM EDT
Completed Phase 3 Interventional Results available

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

NCT01694771
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Placebo matching Olodaterol, Olodaterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
1,134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
90
States / cities
Florence, Alabama • Jasper, Alabama • Phoenix, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Sep 25, 2026, 6:28 PM EDT
Completed No phase listed Observational

Examining the Link Between Obesity, Inflammation, and Response to Asthma Medications

NCT00557180
View directory record Official record
Conditions
Asthma, Obesity
Interventions
Beclomethasone dipropionate HFA, Tiotropium bromide, Salmeterol xinafoate
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 25, 2026, 6:28 PM EDT
Completed Phase 2 Interventional Results available

Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD

NCT03673670
View directory record Official record
Conditions
COPD
Interventions
RPL554 Suspension, Placebo, Tiotropium/olodaterol (Respimat)
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Winter Park, Florida • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Sep 25, 2026, 6:28 PM EDT
Completed Phase 3 Interventional Results available

A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD

NCT02276222
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
SUN-101 50 mcg BID eFlow (CS) nebulizer, Spiriva® 18 mcg QD Handihaler
Drug
Lead sponsor
Sunovion Respiratory Development Inc.
Industry
Eligibility
40 Years and older
Enrollment
1,087 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
83
States / cities
Andalusia, Alabama • Birmingham, Alabama • Jasper, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Sep 25, 2026, 6:28 PM EDT
Completed Phase 2 Interventional Results available

(Hyoscine Butylbromide) for Abdominal Pain Associated With Cramping on Demand Basis

NCT00932737
View directory record Official record
Conditions
Abdominal Pain
Interventions
Placebo, HBB 20 mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
19
States / cities
Westlake Village, California • Hollywood, Florida • Jupiter, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Sep 25, 2026, 6:28 PM EDT
Completed Phase 2Phase 3 Interventional Results available

26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00463567
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive
Interventions
Indacaterol, Formoterol (12 µg b.i.d.), Tiotropium (18 µg o.d.), Placebo to Indacaterol, Placebo to Formoterol
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
2,059 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
221
States / cities
Anniston, Alabama • Birmingham, Alabama • Homewood, Alabama + 163 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2011 · Synced Sep 25, 2026, 6:28 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis

NCT00737100
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Placebo Respimat, Tiotropium bromide 5 mcg, tiotropium bromide-low dose-2.5mcg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
Not listed
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
26
States / cities
Tucson, Arizona • San Diego, California • Jacksonville, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Sep 25, 2026, 6:28 PM EDT
Completed Phase 4 Interventional Results available

A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

NCT00784550
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium Bromide, Fluticasone Propionate/Salmeterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 99 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
35
States / cities
Riverside, California • Fort Collins, Colorado • Clearwater, Florida + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Sep 25, 2026, 6:28 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

NCT05886660
View directory record Official record
Conditions
Motion Sickness, Space, Motion Sickness, Sea Sickness
Interventions
DPI-386 Nasal Gel, Placebo Nasal Gel
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Sep 25, 2026, 6:28 PM EDT